Europe
Carrick Therapeutics, Roche Partner for Breast Cancer Combination Trial
The Phase Ib/II trial will evaluate Carrick's CDK7 inhibitor samuraciclib and Roche's giredestrant in HR-positive, HER2-negative metastatic breast cancer.
Genomes of Advanced Neuroendocrine Neoplasms Unveil Subtypes, Treatment Clues
By sequencing dozens of locally advanced or metastatic neuroendocrine neoplasm samples, researchers detected somatic mutations that varied with primary tumor site and subtype.
Inspirata Partners With UK Health Providers to Evaluate AI Software for Cancer Clinical Trials
The pilot programs will evaluate how artificial intelligence-based automation can improve matching patients with cancer to early-phase clinical trials.
Lantern Pharma Reacquires Irofulven From Allarity Therapeutics; Plans Bladder, Prostate Cancer Trial
In reacquiring the rights to the agent, which it out-licensed in 2015, Lantern is also gaining rights to Allarity's DRP technology to predict patients' responses.
Natera Minimal Residual Disease Test Predicts Oligometastatic CRC Patient Outcomes in New Study
Premium
Investigators analyzed blood samples from patients at two time points after curative-intent surgery, finding that ctDNA MRD status was highly predictive of outcome.